Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × Indocyanine Green × Clear all

Phase

Phase 4 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasms 3 Head and Neck Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Margins of Excision 2 Colorectal Neoplasms 2 Sarcoma 1 Right Hemicolectomy 1 Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Lymphedema 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholecystitis 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Cancer Lymphedema 1

Interventions

Paclitaxel 115 Carboplatin 115 Bevacizumab 76 Gemcitabine 38 pembrolizumab 36 olaparib 32 Cisplatin 27 Docetaxel 26 Cyclophosphamide 26 niraparib 25 liposomal doxorubicin 23 Topotecan 22 Etoposide 17 Doxorubicin 15 Taxes 13 apatinib 12 Letrozole 12 Immunoglobulin G 11 Filgrastim 11 Drug Therapy 11 Disulfides 11 Albumin-Bound Paclitaxel 11 fludarabine 10 fluzoparib 9 Biopsy 9 durvalumab 8 Specimen Handling 8 Nivolumab 8 Magnetic Resonance Spectroscopy 8 Cytoreduction Surgical Procedures 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04891185 2023-10-05

VIPIDO

Universitaire Ziekenhuizen KU Leuven

Phase 2 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡